title: Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
abstract: Administration of temozolomide to a 46-year-old man with an invasive aggressive prolactin (PRL)-secreting pituitary neoplasm resulted in improvement of the clinical condition and significant decrease of blood PRL levels. Histologic, immunohistochemical, and electron microscopic study demonstrated marked morphological differences in the tumor exposed to temozolomide compared with the unexposed tumor. Necrosis, hemorrhagic areas, accumulation of connective tissue, focal inflammatory infiltration, and neuronal transformation were seen. Immunohistochemical prognostic indicators showed a reduction in growth potential. Based on the clinical, laboratory, and morphological findings, we recommend temozolomide therapy in patients with pituitary tumors not responding adequately to other treatment options.
authors.affiliation: Department of Laboratory Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada M5B 1W8. kovacsk@smh.toronto.on.ca
authors.forename: Kalman
authors.initials: K
authors.lastname: Kovacs
authors.forename: Eva
authors.initials: E
authors.lastname: Horvath
authors.forename: Luis V
authors.initials: LV
authors.lastname: Syro
authors.forename: Humberto
authors.initials: H
authors.lastname: Uribe
authors.forename: Luis C
authors.initials: LC
authors.lastname: Penagos
authors.forename: Leon D
authors.initials: LD
authors.lastname: Ortiz
authors.forename: Camilo E
authors.initials: CE
authors.lastname: Fadul
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008854:Microscopy, Electron; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000648:ultrastructure; D011388:Prolactin / Q000097:blood / Q000378:metabolism; D015175:Prolactinoma / Q000188:drug therapy* / Q000473:pathology / Q000648:ultrastructure; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D011388:Prolactin; D000077204:Temozolomide